Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion received Phase 3 Clinical Trial Application (IND) approval from the US Food and Drug Administration (FDA) for CT-P44, a biosimilar candidate referencing Darzalex.
약업신문
📊 Key Disclosure Content & Financial Highlights
- Overview Celltrion
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: US FDA Approval of Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar)
- Regulatory Authority: US Food and Drug Administration (FDA) 약업신문
- Key Dates (Local Time): Application Date 2024-11-29 / Approval Date 2024-12-26
- Confirmation Date: 2024-12-27 (Date FDA approval was confirmed) Celltrion
- Clinical Trial Details Celltrion
- Study Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group Phase 3 Trial to Compare the Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
- Phase: Global Phase 3 한국보건산업진흥원
- Target Indication: Refractory or relapsed multiple myeloma
- Registration Number: EU CT number 2024-518588-36-00
- Patient Count: 486 subjects 데일리안
- Duration: 2-year trial period 데이터투자
- Purpose: To compare efficacy and safety between CT-P44 and reference drug Darzalex to demonstrate biosimilarity 한국보건산업진흥원
- Regulatory Process & Investment Risks
- Celltrion plans to demonstrate biosimilarity in efficacy and safety compared to the reference product Darzalex through this Phase 3 trial.
- Statistically, the probability of a clinical-stage drug candidate receiving final authorization is approximately 10%. Commercialization plans may be altered or abandoned based on trial outcomes. 조선일보
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Clinical Trial Progress and Patient Recruitment in the US
This disclosure serves as official notification that Celltrion has received US FDA approval for its Phase 3 Clinical Trial Plan for CT-P44. Tracking whether patient enrollment and clinical milestones proceed according to schedule is important for evaluating the execution of the approved trial plan. Relevant updates can be confirmed through subsequent periodic reports or official IR announcements.
한국금융신문
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
데일리안
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
